A novel class of bis-and tris-chelate diam(m)inebis(dicarboxylato) platinum(IV) complexes as potential anticancer prodrugs

Journal of Medicinal Chemistry

Volumn 57, Issue 15, 2014, Pages 6751-6764

  Varbanov, Hristo P ^a   Göschl, Simone ^a   Heffeter, Petra ^a,b   Theiner, Sarah ^a   Roller, Alexander ^a   Jensen, Frank ^c   Jakupec, Michael A ^a   Berger, Walter ^a,b   Galanski, Markus ^a   Keppler, Bernhard K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

(DIAMINOCYCLOHEXANE)BIS(MALONATO)PLATINUM; (DIAMINOCYCLOHEXANE)BIS(OXALATO)PLATINUM; AMMINE(CYCLOHEXYLAMINE)BIS(MALONATO)PLATINUM; ANTINEOPLASTIC AGENT; BIS(1,1 CYCLOBUTANEDICARBOXYLATO)ETHANE 1,2 DIAMINEPLATINUM; BIS(ETHYLAMINE)BIS(MALONATO)PLATINUM; BIS(ETHYLAMINE)TETRAHYDROXIDOPLATINUM; CARBOPLATIN; CHELATE; CISPLATIN; DIAM(M)INEBIS(DICARBOXYLATO)PLATINUM COMPLEX; DIAMMINEBIS(MALONATO)PLATINUM; ETHANE 1,2 DIAMINEBIS(3 METHYLMALONATO)PLATINUM; ETHANE 1,2 DIAMINEBIS(MALONATO)PLATINUM; ETHANE 1,2 DIAMINEBIS(OXALATO)PLATINUM; MALONIC ACID; METHYLMALONIC ACID; OXALIC ACID; OXALIPLATIN; PLATINUM COMPLEX; PRODRUG; SATRAPLATIN; UNCLASSIFIED DRUG; COORDINATION COMPOUND; DIAMINOCYCLOHEXANE)BIS(MALONATO)PLATINUM(IV); PLATINUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; COLORIMETRY; DRUG CYTOTOXICITY; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LEUKEMIA L 1210; LIPOPHILICITY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PHYSICAL CHEMISTRY; THERMOGRAVIMETRY; TUMOR CELL LINE; X RAY DIFFRACTION; ANIMAL; BAGG ALBINO MOUSE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; COLONIC NEOPLASMS; DBA MOUSE; DRUG SCREENING; LEUKEMIA L1210; OXIDATION REDUCTION REACTION; QUANTUM THEORY; SCID MOUSE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; THERMODYNAMICS; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHYSICAL; COLONIC NEOPLASMS; COORDINATION COMPLEXES; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LEUKEMIA L1210; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, SCID; MODELS, MOLECULAR; ORGANOPLATINUM COMPOUNDS; OXIDATION-REDUCTION; PLATINUM; QUANTUM THEORY; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 84906100011     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500791c     Document Type: Article

References (54)

1. Wheate, N. J.; Walker, S.; Craig, G. E.; Oun, R. The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Trans. 2010, 39, 8113-8127
2. Einhorn, L. H. Cisplatin and the revolution of treatment of germ cell tumors, 11th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy, Verona, Italy, October 11-14, 2012.
3. Galanski, M.; Jakupec, M. A.; Keppler, B. K. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches Curr. Med. Chem. 2005, 12, 2075-2094
4. Kelland, L. The resurgence of platinum-based cancer chemotherapy Nat. Rev. Cancer 2007, 7, 573-584
5. Graf, N.; Lippard, S. J. Redox activation of metal-based prodrugs as a strategy for drug delivery Adv. Drug Delivery Rev. 2012, 64, 993-1004
6. Hall, M. D.; Mellor, H. R.; Callaghan, R.; Hambley, T. W. Basis for design and development of platinum(IV) anticancer complexes J. Med. Chem. 2007, 50, 3403-3411
7. Harper, B. W.; Krause-Heuer, A. M.; Grant, M. P.; Manohar, M.; Garbutcheon-Singh, K. B.; Aldrich-Wright, J. R. Advances in platinum chemotherapeutics Chem.-Eur. J. 2010, 16, 7064-7077
8. Johnstone, T. C.; Wilson, J. J.; Lippard, S. J. Monofunctional and higher-valent platinum anticancer agents Inorg. Chem. 2013, 52, 12234-12249
9. Varbanov, H. P.; Jakupec, M. A.; Roller, A.; Jensen, F.; Galanski, M.; Keppler, B. K. Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes J. Med. Chem. 2013, 56, 330-344
10. Wilson, J. J.; Lippard, S. J. Synthetic methods for the preparation of platinum anticancer complexes Chem. Rev. 2014, 114, 4470-4495
11. Sova, P.; Mistr, A.; Kroutil, A.; Semerad, M.; Chlubnova, H.; Hruskova, V.; Chladkova, J.; Chladek, J. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato) (1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV) Cancer Chemother. Pharmacol. 2011, 67, 1247-1256
12. Hall, M. D.; Hambley, T. W. Platinum(IV) antitumour compounds: their bioinorganic chemistry Coord. Chem. Rev. 2002, 232, 49-67
13. 3(5′-GMP)] by NMR spectroscopy and ESI-MS Inorg. Chim. Acta 2000, 300-302, 783-789
14. Schilder, R. J.; LaCreta, F. P.; Perez, R. P.; Johnson, S. W.; Brennan, J. M.; Rogatko, A.; Nash, S.; McAleer, C.; Hamilton, T. C.; Roby, D. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule Cancer Res. 1994, 54, 709-717
15. Chen, C. K. J.; Zhang, J. Z.; Aitken, J. B.; Hambley, T. W. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD 1 cancer cells J. Med. Chem. 2013, 56, 8757-8764
16. Barefoot, R. R. Speciation of platinum compounds: a review of recent applications in studies of platinum anticancer drugs J. Chromatogr. B 2001, 751, 205-211
17. Raynaud, F. I.; Mistry, P.; Donaghue, A.; Poon, G. K.; Kelland, L. R.; Barnard, C. F. J.; Murrer, B. A.; Harrap, K. R. Biotransformation of the platinum drug JM216 following oral administration to cancer patients Cancer Chemother. Pharmacol. 1996, 38, 155-162
18. Carr, J. L.; Tingle, M. D.; McKeage, M. J. Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro Cancer Chemother. Pharmacol. 2006, 57, 483-490
19. 2(cis-1,4-DACH)] Dalton Trans. 2011, 40, 12877-12885
20. Chin, C. F.; Tian, Q.; Setyawati, M. I.; Fang, W.; Tan, E. S. Q.; Leong, D. T.; Ang, W. H. Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation J. Med. Chem. 2012, 55, 7571-7582
21. Feazell, R. P.; Nakayama-Ratchford, N.; Dai, H.; Lippard, S. J. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design J. Am. Chem. Soc. 2007, 129, 8438-8439
22. Pichler, V.; Goeschl, S.; Meier, S. M.; Roller, A.; Jakupec, M. A.; Galanski, M.; Keppler, B. K. Bulky N,N-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes Inorg. Chem. 2013, 52, 8151-8162
23. Zhang, J. Z.; Bonnitcha, P.; Wexselblatt, E.; Klein, A. V.; Najajreh, Y.; Gibson, D.; Hambley, T. W. Facile preparation of mono-, di-and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design Chem.-Eur. J. 2013, 19, 1672-1676
24. Song, R.; Kim, K. M.; Sohn, Y. S. Synthesis and characterization of novel tricarboxylatoplatinum(IV) complexes. Nucleophilic substitution of (diamine)-tetrahydroxoplatinum(IV) with carboxylic acid Inorg. Chim. Acta 2002, 338, 89-93
25. Barnard, C. F. J.; Vollano, J. F.; Chaloner, P. A.; Dewa, S. Z. Studies on the oral anticancer drug JM-216: synthesis and characterization of isomers and related complexes Inorg. Chem. 1996, 35, 3280-3284
26. Varbanov, H. P.; Valiahdi, S. M.; Kowol, C. R.; Jakupec, M. A.; Galanski, M.; Keppler, B. K. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs Dalton Trans. 2012, 41, 14404-14415
27. Reithofer, M. R.; Valiahdi, S. M.; Jakupec, M. A.; Arion, V. B.; Egger, A.; Galanski, M.; Keppler, B. K. Novel di-and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination J. Med. Chem. 2007, 50, 6692-6699
28. Hoffmeister, B. R.; Adib-Razavi, M. S.; Jakupec, M. A.; Galanski, M.; Keppler, B. K. Diamminetetrakis(carboxylato)platinum(IV) complexes-synthesis, characterization, and cytotoxicity Chem. Biodiversity 2012, 9, 1840-1848
29. o/w values of several Pt(II) complexes J. Inorg. Biochem. 2006, 100, 1199-1207
30. Reithofer, M. R.; Bytzek, A. K.; Valiahdi, S. M.; Kowol, C. R.; Groessl, M.; Hartinger, C. G.; Jakupec, M. A.; Galanski, M.; Keppler, B. K. Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes J. Inorg. Biochem. 2011, 105, 46-51
31. Valko, K. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution J. Chromatogr. A 2004, 1037, 299-310
32. Nasal, A.; Siluk, D.; Kaliszan, R. Chromatographic retention parameters in medicinal chemistry and molecular pharmacology Curr. Med. Chem. 2003, 10, 381-426
33. Ermondi, G.; Caron, G.; Ravera, M.; Gabano, E.; Bianco, S.; Platts, J. A.; Osella, D. Molecular interaction fields vs. quantum-mechanical-based descriptors in the modelling of lipophilicity of platinum(IV) complexes Dalton Trans. 2013, 42, 3482-3489
34. Varbanov, H.; Valiahdi, S. M.; Legin, A. A.; Jakupec, M. A.; Roller, A.; Galanski, M.; Keppler, B. K. Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin Eur. J. Med. Chem. 2011, 46, 5456-5464
35. Banfić, J.; Legin, A. A.; Jakupec, M. A.; Galanski, M.; Keppler, B. K. Platinum(IV) complexes featuring one or two axial ferrocene bearing ligands-synthesis, characterization, and cytotoxicity Eur. J. Inorg. Chem. 2014, 2014, 484-492
36. Zhang, J. Z.; Wexselblatt, E.; Hambley, T. W.; Gibson, D. Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate Chem. Commun. 2012, 48, 847-849
37. Wexselblatt, E.; Gibson, D. What do we know about the reduction of Pt(IV) pro-drugs? J. Inorg. Biochem. 2012, 117, 220-229
38. Pestieau, S. R.; Belliveau, J. F.; Griffin, H.; Stuart, O. A.; Sugarbaker, P. H. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies J. Surg. Oncol. 2001, 76, 106-114
39. Jerremalm, E.; Wallin, I.; Ehrsson, H. New insights into the biotransformation and pharmacokinetics of oxaliplatin J. Pharm. Sci. 2009, 98, 3879-3885
40. Zheligovskaya, N. N.; Melnikov, M. Y. Method for producing platinum(IV) complexes. WO2003066526A1, 2003.
41. Kim, K. M.; Lee, Y.-A.; Lee, S. S.; Sohn, Y. S. Facile synthesis and structural properties of (diamine)tetracarboxylatoplatinum(IV) complexes Inorg. Chim. Acta 1999, 292, 52-56
42. Brandon, R. J.; Dabrowiak, J. C. Synthesis, characterization, and properties, of a group of platinum(IV) complexes J. Med. Chem. 1984, 27, 861-865
43. Meelich, K.; Galanski, M.; Arion, V. B.; Keppler, B. K. Bis(2-amino alcohol-κN)dicarboxylatoplatinum(II) complexes-elegant synthesis via ring-opening of bis(2-amino alcoholato-κ2N,O)platinum(II) species with dicarboxylic acids Eur. J. Inorg. Chem. 2006, 2476-2483
44. SAINT-Plus, version 7.06a, and APEX2; Bruker-Nonius AXS Inc.: Madison, WI, 2004.
45. Sheldrick, G. M. A short history of SHELX Acta Crystallogr., Sect. A 2008, 64, 112-122
46. Soczewinski, E.; Wachtmeister, C. A. The relation between the composition of certain ternary two-phase solvent systems and RM values J. Chromatogr. 1962, 7, 311-320
47. Snyder, L. R.; Dolan, J. W.; Gant, J. R. Gradient elution in high-performance liquid chromatography. I. Theoretical basis for reversed-phase systems J. Chromatogr. 1979, 165, 3-30
48. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 09, revision A.02; Gaussian, Inc.: Wallingford, CT, 2009.
49. Chai, J. D.; Head-Gordon, M. Systematic optimization of long-range corrected hybrid density functionals J. Chem. Phys. 2008, 128, 084106-1-084106-15
50. Weigend, F.; Ahlrichs, R. Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: design and assessment of accuracy Phys. Chem. Chem. Phys. 2005, 7, 3297-3305
51. Andrae, D.; Haeussermann, U.; Dolg, M.; Stoll, H.; Preuss, H. Energy-adjusted ab initio pseudopotentials for the second and third row transition elements Theor. Chim. Acta 1990, 77, 123-141
52. Miertus, S.; Scrocco, E.; Tomasi, J. Electrostatic interaction of a solute with a continuum. A direct utilization of ab initio molecular potentials for the prevision of solvent effects Chem. Phys. 1981, 55, 117-129
53. Foresman, J. B.; Keith, T. A.; Wiberg, K. B.; Snoonian, J.; Frisch, M. J. Solvent effects 5. The influence of cavity shape, truncation of electrostatics, and electron correlation on ab initio reaction field calculations J. Phys. Chem. 1996, 100, 16098-16104
54. Reed, A. E.; Weinstock, R. B.; Weinhold, F. Natural-population analysis J. Chem. Phys. 1985, 83, 735-746